Neuronal-immune interactions in mediating stress effects in the etiology and course of schizophrenia: Role of the amygdala in developmental co-ordination

Medical Hypotheses

Volumn 76, Issue 1, 2011, Pages 54-60

  Anderson, George ^a  

^a CRC   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BAG 1 PROTEIN; COLECALCIFEROL; DOPAMINE; HYDROCORTISONE; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 18; KYNURENIC ACID; MELATONIN; NEUROPEPTIDE Y; QUINOLINIC ACID; REACTIVE OXYGEN METABOLITE;

AMYGDALOID NUCLEUS; APOPTOSIS; ARTICLE; BEHAVIOR; BRAIN CORTEX; CELL INTERACTION; CONSCIOUSNESS; CORPUS STRIATUM; DISEASE COURSE; HUMAN; IMMUNE RESPONSE; NERVE CELL; NONHUMAN; NUCLEUS ACCUMBENS; PRENATAL PERIOD; PSYCHOMOTOR PERFORMANCE; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; STRESS; SYMPTOM; THINKING;

AMYGDALA; HUMANS; HYDROCORTISONE; KYNURENINE; SCHIZOPHRENIA; STRESS, PSYCHOLOGICAL;

EID: 78650175741     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2010.08.029     Document Type: Article

References (112)

1. O'Donnell K., O'Connor T.G., Glover V. Prenatal stress and neurodevelopment of the child: focus on the HPA axis and role of the placenta. Dev Neurosci 2009, 31(4):285-292.
2. Râdulescu A. A multi-etiology model of systemic degeneration in schizophrenia. J Theor Biol. 2009, 259(2):269-279.
3. Schlotz W., Phillips D.I. Fetal origins of mental health: evidence and mechanisms. Brain Behav Immun 2009, 23(7):905-916.
4. Brenner K., Liu A., Laplante D.P., Lupien S., Pruessner J.C., Ciampi A., et al. Cortisol response to a psychosocial stressor in schizophrenia: blunted, delayed, or normal?. Psychoneuroendocrinology 2009, 34(6):859-868.
5. Laugeray A., Launay J.M., Callebert J., Surget A., Belzung C., Barone P.R. Peripheral and cerebral metabolic abnormalities of the tryptophan-kynurenine pathway in a murine model of major depression. Behav Brain Res 2010, 210(1):84-91.
6. Zmarowski A., Wu H.Q., Brooks J.M., Potter M.C., Pellicciari R., Schwarcz R., et al. Astrocyte-derived kynurenic acid modulates basal and evoked cortical acetylcholine release. Eur J Neurosci 2009, 29(3):529-538.
7. Müller N., Myint A.M., Schwarz M.J. The impact of neuroimmune dysregulation on neuroprotection and neurotoxicity in psychiatric disorders - relation to drug treatment. Dialogues Clin Neurosci 2009, 11(3):319-332.
8. Jhamandas K.H., Boegman R.J., Beninger R.J., Miranda A.F., Lipic K.A. Excitotoxicity of quinolinic acid: modulation by endogenous antagonists. Neurotox Res 2000, 2(2-3):139-155.
9. Erhardt S., Olsson S.K., Engberg G. Pharmacological manipulation of kynurenic acid: potential in the treatment of psychiatric disorders. CNS Drugs 2009, 23(2):91-101.
10. Miller C.L., Murakami P., Ruczinski I., Ross R.G., Sinkus M., Sullivan B., et al. Two complex genotypes relevant to the kynurenine pathway and melanotropin function show association with schizophrenia and bipolar disorder. Schizophr Res 2009, 113(2-3):259-267.
11. Olsson S.K., Samuelsson M., Saetre P., Lindström L., Jönsson E.G., Nordin C., et al. Elevated levels of kynurenic acid in the cerebrospinal fluid of patients with bipolar disorder. J Psychiatry Neurosci 2010, 35(3):195-199.
12. Miller C.L., Llenos I.C., Dulay J.R., Weis S. Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder. Brain Res 2006, 1073-1074:25-37.
13. Marek G.J., Behl B., Bespalov A.Y., Gross G., Lee Y., Schoemaker H. Glutamatergic (N-methyl-d-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain?. Mol Pharmacol 2010, 77(3):317-326.
14. Chess A.C., Simoni M.K., Alling T.E., Bucci D.J. Elevations of endogenous kynurenic acid produce spatial working memory deficits. Schizophr Bull 2007, 33(3):797-804.
15. Chess A.C., Landers A.M., Bucci D.J. l-Kynurenine treatment alters contextual fear conditioning and context discrimination but not cue-specific fear conditioning. Behav Brain Res 2009, 201(2):325-331.
16. Sacco K.A., Creeden C., Reutenauer E.L., George T.P. Effects of galantamine on cognitive deficits in smokers and non-smokers with schizophrenia. Schizophr Res 2008, 103(1-3):326-327.
17. Linderholm K.R., Andersson A., Olsson S., Olsson E., Snodgrass R., Engberg G., et al. Activation of rat ventral tegmental area dopamine neurons by endogenous kynurenic acid: a pharmacological analysis. Neuropharmacology 2007, 53(8):918-924.
18. Srivastava V., Deshpande S.N., Thelma B.K. Dopaminergic pathway gene polymorphisms and genetic susceptibility to schizophrenia among north Indians. Neuropsychobiology 2010, 61(2):64-70.
19. De Luca V., Tharmalingam S., Zai C., Potapova N., Strauss J., Vincent J., et al. Association of HPA axis genes with suicidal behaviour in schizophrenia. J Psychopharmacol 2010, 24(5):677-682.
20. You J.M., Yun S.J., Nam K.N., Kang C., Won R., Lee E.H. Mechanism of glucocorticoid-induced oxidative stress in rat hippocampal slice cultures. Can J Physiol Pharmacol 2009, 87(6):440-447.
21. Chakraborty S., Kaushik D.K., Gupta M., Basu A. Inflammasome signaling at the heart of central nervous system pathology. J Neurosci Res 2010, 88(8):1615-1631.
22. Kelly S.P., Wood C.M. Cortisol stimulates calcium transport across cultured gill epithelia from freshwater rainbow trout. In Vitro Cell Dev Biol Anim 2008, 44(3-4):96-104.
23. Shini S., Shini A., Kaiser P. Cytokine and chemokine gene expression profiles in heterophils from chickens treated with corticosterone. Stress 2010, 13(3):185-194.
24. Ojala JO, Anderson G. Unpublished data.
25. Silva R., Mesquita A.R., Bessa J., Sousa J.C., Sotiropoulos I., Leão P., et al. Lithium blocks stress-induced changes in depressive-like behavior and hippocampal cell fate: the role of glycogen-synthase-kinase-3beta. Neuroscience 2008, 152(3):656-669.
26. Hunsberger J.G., Austin D.R., Chen G., Manji H.K. Cellular mechanisms underlying affective resiliency: the role of glucocorticoid receptor- and mitochondrially-mediated plasticity. Brain Res 2009, 1293:76-84.
27. Zhou R., Gray N.A., Yuan P., Li X., Chen J., Chen G., et al. The anti-apoptotic, glucocorticoid receptor cochaperone protein BAG-1 is a long-term target for the actions of mood stabilizers. J Neurosci 2005, 25(18):4493-4502.
28. Xapelli S., Bernardino L., Ferreira R., Grade S., Silva A.P., Salgado J.R., et al. Interaction between neuropeptide Y (NPY) and brain-derived neurotrophic factor in NPY-mediated neuroprotection against excitotoxicity: a role for microglia. Eur J Neurosci 2008, 27(8):2089-2102.
29. Goghari V.M., Sponheim S.R., MacDonald A.W. The functional neuroanatomy of symptom dimensions in schizophrenia: a qualitative and quantitative review of a persistent question. Neurosci Biobehav Rev 2010, 34(3):468-486.
30. Jones J.L., Day J.J., Aragona B.J., Wheeler R.A., Wightman R.M., Carelli R.M. Basolateral amygdala modulates terminal dopamine release in the nucleus accumbens and conditioned responding. Biol Psychiatry 2010, 67(8):737-744.
31. McGinty V.B., Grace A.A. Activity-dependent depression of medial prefrontal cortex inputs to accumbens neurons by the basolateral amygdala. Neuroscience 2009, 162(4):1429-1436.
32. McGinty V.B., Grace A.A. Timing-dependent regulation of evoked spiking in nucleus accumbens neurons by integration of limbic and prefrontal cortical inputs. J Neurophysiol 2009, 101(4):1823-1835.
33. Ito M., Nagai T., Kamei H., Nakamichi N., Nabeshima T., Takuma K., et al. Involvement of tissue plasminogen activator-plasmin system in depolarization-evoked dopamine release in the nucleus accumbens of mice. Mol Pharmacol 2006, 70(5):1720-1725.
34. Nagappan G., Zaitsev E., Senatorov V.V., Yang J., Hempstead B.L., Lu B. Control of extracellular cleavage of ProBDNF by high frequency neuronal activity. Proc Natl Acad Sci USA 2009, 106(4):1267-1272.
35. Margulies D.S., Kelly A.M., Uddin L.Q., Biswal B.B., Castellanos F.X., Milham M.P. Mapping the functional connectivity of anterior cingulate cortex. Neuroimage 2007, 37(2):579-588.
36. Williams L.M., Liddell B.J., Kemp A.H., Bryant R.A., Meares R.A., Peduto A.S., et al. Amygdala-prefrontal dissociation of subliminal and supraliminal fear. Hum Brain Mapp 2006, 27(8):652-661.
37. Chong R.Y., Oswald L., Yang X., Uhart M., Lin P.I., Wand G.S. The mu-opioid receptor polymorphism A118G predicts cortisol responses to naloxone and stress. Neuropsychopharmacology 2006, 31(1):204-211.
38. Reddy D.S., Kulkarni S.K. Chronic neurosteroid treatment prevents the development of morphine tolerance and attenuates abstinence behavior in mice. Eur J Pharmacol 1997, 337(1):19-25.
39. Love T.M., Stohler C.S., Zubieta J.K. Positron emission tomography measures of endogenous opioid neurotransmission and impulsiveness traits in humans. Arch Gen Psychiatry 2009, 66(10):1124-1134.
40. Crick F.C., Koch C. What is the function of the claustrum?. Philos Trans R Soc Lond B Biol Sci 2005, 360(1458):1271-1279.
41. Markowitsch H.J., Irle E., Bang-Olsen R., Flindt-Egebak P. Claustral efferents to the cat's limbic cortex studied with retrograde and anterograde tracing techniques. Neuroscience 1984, 12(2):409-425.
42. McGrath J., Eyles D., Mowry B., Yolken R., Buka S. Low maternal vitamin D as a risk factor for schizophrenia: a pilot study using banked sera. Schizophr Res 2003, 63(1-2):73-78.
43. Anderson G. Prenatal corticosteroids: pretermer outcomes, stress, schizophrenia, multiple sclerosis and the developmental role of melatonin and vitamin D3. J Pedia Adol Gyn 2010, 23(5):317-320.
44. Clarke M.C., Tanskanen A., Huttunen M., Whittaker J.C., Cannon M. Evidence for an interaction between familial liability and prenatal exposure to infection in the causation of schizophrenia. Am J Psychiatry 2009, 166(9):1025-1030.
45. Maier W., Zobel A., Wagner M. Schizophrenia and bipolar disorder: differences and overlaps. Curr Opin Psychiatry 2006, 19(2):165-170.
46. Gómez-González B., Escobar A. Prenatal stress alters microglial development and distribution in postnatal rat brain. Acta Neuropathol 2010, 119(3):303-315.
47. Muñoz-Hoyos A., Molina-Carballo A., Macías M., Rodríguez-Cabezas T., Martín-Medina E., Narbona-López E., et al. Comparison between tryptophan methoxyindole and kynurenine metabolic pathways in normal and preterm neonates and in neonates with acute fetal distress. Eur J Endocrinol 1998, 139(1):89-95.
48. Salm A.K., Pavelko M., Krouse E.M., Webster W., Kraszpulski M., Birkle D.L. Lateral amygdaloid nucleus expansion in adult rats is associated with exposure to prenatal stress. Brain Res Dev Brain Res 2004, 148(2):159-167.
49. Bergstrom H.C., Smith R.F., Mollinedo N.S., McDonald C.G. Chronic nicotine exposure produces lateralized, age-dependent dendritic remodeling in the rodent basolateral amygdala. Synapse 2010, 64(10):754-764.
50. Weinstock M. The long-term behavioural consequences of prenatal stress. Neurosci Biobehav Rev 2008, 32(6):1073-1086.
51. Rogers R.D., Moeller F.G., Swann A.C., Clark L. Recent research on impulsivity in individuals with drug use and mental health disorders: implications for alcoholism. Alcohol Clin Exp Res 2010, 34(8):1319-1333.
52. Solis O., Vázquez-Roque R.A., Camacho-Abrego I., Gamboa C., De La Cruz F., Zamudio S., et al. Decreased dendritic spine density of neurons of the prefrontal cortex and nucleus accumbens and enhanced amphetamine sensitivity in postpubertal rats after a neonatal amygdala lesion. Synapse 2009, 63(12):1143-1153.
53. Bissière S., Humeau Y., Lüthi A. Dopamine gates LTP induction in lateral amygdala by suppressing feedforward inhibition. Nat Neurosci 2003, 6(6):587-592.
54. Harding A.J., Stimson E., Henderson J.M., Halliday G.M. Clinical correlates of selective pathology in the amygdala of patients with Parkinson's disease. Brain 2002, 125(Pt 11):2431-2445.
55. Woo T.U., Walsh J.P., Benes F.M. Density of glutamic acid decarboxylase 67 messenger RNA-containing neurons that express the N-methyl-d-aspartate receptor subunit NR2A in the anterior cingulate cortex in schizophrenia and bipolar disorder. Arch Gen Psychiatry 2004, 61(7):649-657.
56. Woo T.U., Shrestha K., Lamb D., Minns M.M., Benes F.M. N-methyl-d-aspartate receptor and calbindin-containing neurons in the anterior cingulate cortex in schizophrenia and bipolar disorder. Biol Psychiatry 2008, 64(9):803-809.
57. Benes F.M. Amygdalocortical circuitry in schizophrenia: from circuits to molecules. Neuropsychopharmacology 2010, 35(1):239-257.
58. Charych E.I., Liu F., Moss S.J., Brandon N.J. GABA(A) receptors and their associated proteins: implications in the etiology and treatment of schizophrenia and related disorders. Neuropharmacology 2009, 57(5-6):481-495.
59. Sun W., Dan Y. Layer-specific network oscillation and spatiotemporal receptive field in the visual cortex. Proc Natl Acad Sci USA 2009, 106(42):17986-17991.
60. Czyrak A., Czepiel K., Maćkowiak M., Chocyk A., Wedzony K. Serotonin 5-HT1A receptors might control the output of cortical glutamatergic neurons in rat cingulate cortex. Brain Res 2003, 989(1):42-51.
61. van Vulpen E.H., Verwer R.W. Organization of projections from the mediodorsal nucleus of the thalamus to the basolateral complex of the amygdala in the rat. Brain Res 1989, 500(1-2):389-394.
62. Markowitsch H.J., Pritzel M. Prefrontal cortex of the guinea pig (Cavia porcellus) defined as cortical projection area of the thalamic mediodorsal nucleus. Brain Behav Evol 1981, 18(1-2):80-95.
63. Del Río M.R., DeFelipe J. A study of SMI 32-stained pyramidal cells, parvalbumin-immunoreactive chandelier cells, and presumptive thalamocortical axons in the human temporal neocortex. J Comp Neurol 1994, 342(3):389-408.
64. Zaitsev A.V., Povysheva N.V., Gonzalez-Burgos G., Rotaru D., Fish K.N., Krimer L.S., et al. Interneuron diversity in layers 2-3 of monkey prefrontal cortex. Cereb Cortex 2009, 19(7):1597-1615.
65. Pierri J.N., Chaudry A.S., Woo T.U., Lewis D.A. Alterations in chandelier neuron axon terminals in the prefrontal cortex of schizophrenic subjects. Am J Psychiatry 1999, 156(11):1709-1719.
66. Vann S.D., Brown M.W., Aggleton J.P. Fos expression in the rostral thalamic nuclei and associated cortical regions in response to different spatial memory tests. Neuroscience 2000, 101(4):983-991.
67. Aggleton J.P., Brown M.W. Episodic memory, amnesia, and the hippocampal-anterior thalamic axis. Behav Brain Sci 1999, 22(3):425-444. discussion 444-89.
68. Raizada R.D., Grossberg S. Towards a theory of the laminar architecture of cerebral cortex: computational clues from the visual system. Cereb Cortex 2003, 13(1):100-113.
69. Carlson JM, Greenberg T, Rubin D, Mujica-Parodi LR. Feeling anxious: anticipatory amygdalo-insular response predicts the feeling of anxious anticipation. Soc Cogn Affect Neurosci. 2010 Apr 23.
70. Tseng K.Y., Lewis B.L., Hashimoto T., Sesack S.R., Kloc M., Lewis D.A., et al. A neonatal ventral hippocampal lesion causes functional deficits in adult prefrontal cortical interneurons. J Neurosci 2008, 28(48):12691-12699.
71. Hazelton J.L., Petrasheuskaya M., Fiskum G., Kristián T. Cyclophilin D is expressed predominantly in mitochondria of gamma-aminobutyric acidergic interneurons. J Neurosci Res 2009, 87(5):1250-1259.
72. Azzolin L., von Stockum S., Basso E., Petronilli V., Forte M.A., Bernardi P. The mitochondrial permeability transition from yeast to mammals. FEBS Lett 2010, 584(12):2504-2509.
73. Sayeed I., Parvez S., Wali B., Siemen D., Stein D.G. Direct inhibition of the mitochondrial permeability transition pore: a possible mechanism for better neuroprotective effects of allopregnanolone over progesterone. Brain Res 2009, 1263:165-173.
74. Kubota M, Kasahara T, Iwamoto K, Komori A, Ishiwata M, Miyauchi T, et al. Therapeutic implications of down-regulation of cyclophilin D in bipolar disorder. Int J Neuropsychopharmacol 2010 Apr 15; 1-14.
75. Menon R.R., Barta P.E., Aylward E.H., Richards S.S., Vaughn D.D., Tien A.Y., et al. Posterior superior temporal gyrus in schizophrenia: grey matter changes and clinical correlates. Schizophr Res 1995, 16(2):127-135.
76. Takahashi T., Malhi G.S., Wood S.J., Yücel M., Walterfang M., Kawasaki Y., et al. Gray matter reduction of the superior temporal gyrus in patients with established bipolar I disorder. J Affect Disord 2010, 123(1-3):276-282.
77. Baruch I., Hemsley D.R., Gray J.A. Differential performance of acute and chronic schizophrenics in a latent inhibition task. J Nerv Ment Dis 1988, 176:598-606.
78. Linderholm K., Powell S., Olsson E., Holtze M., Snodgrass R., Erhardt S. Role of the NMDA-receptor in Prepulse Inhibition in the Rat. Int J Trypt Res 2010, 3:1-12.
79. Gray N.S., Hemsley D.R., Gray J.A. Abolition of latent inhibition in acute, but not chronic, schizophrenics. Neurol Psychiatr Brain Res 1992, 1:83-89.
80. Nelson B., Rawlings D. Relating schizotypy and personality to the phenomenology of creativity. Schizophr Bull 2010, 36(2):388-399.
81. Braff D.L., Geyer M.A., Swerdlow N.R. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl) 2001, 156(2-3):234-258.
82. Asp L., Holtze M., Powell S.B., Karlsson H., Erhardt S. Neonatal infection with neurotropic influenza A virus induces the kynurenine pathway in early life and disrupts sensorimotor gating in adult Tap1-/- mice. Int J Neuropsychopharmacol 2010, 13(4):475-485.
83. Fuxe K., Jacobsen K.X., Höistad M., Tinner B., Jansson A., Staines W.A., et al. The dopamine D1 receptor-rich main and paracapsular intercalated nerve cell groups of the rat amygdala: relationship to the dopamine innervation. Neuroscience 2003, 119(3):733-746.
84. Coccaro E.F., McCloskey M.S., Fitzgerald D.A., Phan K.L. Amygdala and orbitofrontal reactivity to social threat in individuals with impulsive aggression. Biol Psychiatry 2007, 62(2):168-178.
85. Satterthwaite T.D., Wolf D.H., Loughead J., Ruparel K., Valdez J.N., Siegel S.J., et al. Association of enhanced limbic response to threat with decreased cortical facial recognition memory response in schizophrenia. Am J Psychiatry 2010, 167(4):418-426.
86. Almeida J.R., Versace A., Hassel S., Kupfer D.J., Phillips M.L. Elevated amygdala activity to sad facial expressions: a state marker of bipolar but not unipolar depression. Biol Psychiatry 2010, 67(5):414-421.
87. Brown A.S., Derkits E.J. Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am J Psychiatry 2010, 167(3):261-280.
88. Byrne M., Agerbo E., Bennedsen B., Eaton W.W., Mortensen P.B. Obstetric conditions and risk of first admission with schizophrenia: a Danish national register based study. Schizophr Res 2007, 97(1-3):51-59.
89. Causevic M., Mohaupt M. 11beta-Hydroxysteroid dehydrogenase type 2 in pregnancy and preeclampsia. Mol Aspects Med 2007, 28(2):220-226.
90. Quincozes-Santos A., Bobermin L.D., Kleinkauf-Rocha J., Souza D.O., Riesgo R., Gonçalves C.A., et al. Atypical neuroleptic risperidone modulates glial functions in C6 astroglial cells. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33(1):11-15.
91. Monji A., Kato T., Kanba S. Cytokines and schizophrenia: microglia hypothesis of schizophrenia. Psychiatry Clin Neurosci 2009, 63(3):257-265.
92. Quiros I., Mayo J.C., Garcia-Suarez O., Hevia D., Martin V., Rodríguez C., et al. Melatonin prevents the glucocorticoid receptor inhibition of cell proliferation and toxicity in hippocampal cells by reducing the glucocorticoid receptor nuclear translocation. J. Steroid BioChem. Mol. Biol. 2008, 110:116-124.
93. Leboyer M, Etain B, Jamain S, Henry C, Bellivier F, Bourgeron T. Genetic exploration of the melatoninergic pathway in bipolar disorder. Conference presentation and paper, in preparation.
94. Monteleone P., Natale M., La Rocca A., Maj M. Decreased nocturnal secretion of melatonin in drug-free schizophrenics: no change after subchronic treatment with antipsychotics. Neuropsychobiology 1997, 36(4):159-163.
95. Danel T., Cottencin O., Tisserand L., Touitou Y. Inversion of melatonin circadian rhythm in chronic alcoholic patients during withdrawal: preliminary study on seven patients. Alcohol Alcohol 2009, 44(1):42-45.
96. Reiter R.J., Tan D.X., Osuna C., Gitto E. Actions of melatonin in the reduction of oxidative stress. A review. J Biomed Sci 2000, 7(6):444-458.
97. Martín M., Macías M., León J., Escames G., Khaldy H., Acuña-Castroviejo D. Melatonin increases the activity of the oxidative phosphorylation enzymes and the production of ATP in rat brain and liver mitochondria. Int J Biochem Cell Biol 2002, 34(4):348-357.
98. Marczynski T.J., Yamaguchi N., Ling G.M., Grodzinska L. Sleep induced by the administration of melatonin (5-methoxyn-acetyltryptamine) to the hypothalamus in unrestrained cats. Experientia 1964, 20(8):435-437.
99. Jou S.H., Chiu N.Y., Liu C.S. Mitochondrial dysfunction and psychiatric disorders. Chang Gung Med J 2009, 32(4):370-379.
100. Tardieu S., Micallef J., Gentile S., Blin O. Weight gain profiles of new anti-psychotics: public health consequences. Obes Rev 2003, 4(3):129-138. Review.
101. Chang H.M., Wu U.I., Lan C.T. Melatonin preserves longevity protein (sirtuin 1) expression in the hippocampus of total sleep-deprived rats. J Pineal Res 2009, 47(3):211-220.
102. Anderson G. Melatonin: its inhibition of anti-psychotic side-effects, and an overlooked developmental, and maintenance factor in psychosis. Submitted for publication.
103. Kennedy S.H. Agomelatine: efficacy at each phase of antidepressant treatment. CNS Drugs 2009, 23(Suppl. 2):41-47.
104. Stein D.J., Fincham D., Seedat S., de Bodinat C., Ahokas A. The DSM-IV-based generalized anxiety disorder severity scale: preliminary validation using data from a trial of agomelatine versus placebo. J Nerv Ment Dis 2009, 197(6):391-394.
105. Owen R.T. Agomelatine: a novel pharmacological approach to treating depression. Drugs Today (Barc) 2009, 45(8):599-608.
106. Calabrese J.R., Guelfi J.D., Perdrizet-Chevallier C. Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data. Bipolar Disord 2007, 9(6):628-635. Agomelatine Bipolar Study Group.
107. Anderson G. Some recent treatment options in OCD: amphetamine, caffeine and agomelatine; with overlaps in mechanisms of action. Agomelatine: Why Wait? in press.
108. Kim SO, You JM, Yun SJ, Son MS, Nam KN, Hong JW, et al. Ginsenoside Rb1 and Rg3 Attenuate Glucocorticoid-Induced Neurotoxicity. Cell Mol Neurobiol, 2010 Mar 25.
109. Liu N., Kaplan A.T., Low J., Nguyen L., Liu G.Y., Equils O., et al. Vitamin D induces innate antibacterial responses in human trophoblasts via an intracrine pathway. Biol Reprod 2009, 80(3):398-406.
110. Evans K.N., Nguyen L., Chan J., Innes B.A., Bulmer J.N., Kilby M.D., et al. Effects of 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 on cytokine production by human decidual cells. Biol Reprod 2006, 75(6):816-822.
111. Balogh G., de Boland A.R., Boland R., Barja P. Effect of 1,25(OH)(2)-vitamin D(3) on the activation of natural killer cells: role of protein kinase C and extracellular calcium. Exp Mol Pathol 1999, 67(2):63-74.
112. Holmes V.A., Barnes M.S., Alexander H.D., McFaul P., Wallace J.M. Vitamin D deficiency and insufficiency in pregnant women: a longitudinal study. Br J Nutr 2009, 102(6):876-881.